Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors

Inhibition of the p16(INK4a)/cyclin D/CDK4/6/RB pathway is an effective therapeutic strategy for the treatment of estrogen receptor positive (ER(+)) breast cancer. Although efficacious, current treatment regimens require a dosing holiday due to severe neutropenia potentially leading to an increased...

Descripción completa

Detalles Bibliográficos
Autores principales: Bisi, John E., Sorrentino, Jessica A., Jordan, Jamie L., Darr, David D., Roberts, Patrick J., Tavares, Francis X., Strum, Jay C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522071/
https://www.ncbi.nlm.nih.gov/pubmed/28418845
http://dx.doi.org/10.18632/oncotarget.16216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522071/
https://www.ncbi.nlm.nih.gov/pubmed/28418845
http://dx.doi.org/10.18632/oncotarget.16216

Ejemplares similares